Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03585660 Recruiting - Prostate Cancer Clinical Trials

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

Start date: June 19, 2018
Phase: N/A
Study type: Interventional

The purpose of the proposed research is to test and validate an artificial intelligence-based Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).

NCT ID: NCT03575832 Recruiting - Prostate Cancer Clinical Trials

Watchful Living: A Lifestyle Intervention for Black Prostate Cancer Patients on Active Surveillance and Their Partners

Start date: January 25, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to learn if a social support lifestyle intervention (called Watchful Living) can help African American prostate cancer patients and their partners improve their quality of life, physical activity, diet, and inflammation. This is an investigational study. Up to 80 participants (40 patients and their partners) will be enrolled in this part of the study. All will take part at MD Anderson.

NCT ID: NCT03574571 Recruiting - Prostate Cancer Clinical Trials

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Start date: June 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

NCT ID: NCT03573011 Recruiting - Prostate Cancer Clinical Trials

PSMA PET/CT for Prostate Cancer

NGP2
Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

Prostate cancer is the most frequently occurring male cancer in Belgium. Patients who have been treated for prostate cancer, i.e. by surgery and/or radiotherapy, in a substantial degree suffer from a tumor recurrence, often diagnosed by an increase in serum tumor marker Prostate Specific Antigen (PSA) within the first few years. In these patients with evidence of a tumor recurrence after primary treatment, it is important to most exactly define the location(s) of tumor, to guide appropriate therapy by surgery, radiotherapy and/or hormonotherapy. In so-called oligo-metastatic disease targeted therapy may still be curative and prevent the disease from spreading to distant locations. Therefore it is of paramount importance to have an accurate tool of medical imaging to localize all possible locations to be treated.

NCT ID: NCT03572621 Recruiting - Prostate Cancer Clinical Trials

Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality

PRODUCAN
Start date: July 2018
Phase: N/A
Study type: Interventional

Prostate cancer is the most common cancer in France (54,000 cases in 2011). About 20,000 radical prostatectomies (PR) per year are performed. Despite the progress of PR over the past 20 years, the rate of erectile dysfunction post PR varies between 30 and 90% and only 16% of operated men recover their pre-treatment erections. There is currently no validated post-prostatectomy rehabilitation protocol. The associations of patients, including the National Association of Prostate Cancer Patients have a very strong demand for treatment of sexual problems after treatment.

NCT ID: NCT03572387 Recruiting - Prostate Cancer Clinical Trials

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Start date: June 25, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, randomized, cross-over, pilot study of reprogramming therapy in patients with recurrent PCa based on rising PSA only. The primary objectives are to compare the disease progression-free rate at the end of 12 weeks between 5-AZA+ATRA and no therapy and to assess safety of the 5-AZA and ATRA combination. All study enrollees will receive Lupron. After one month, they will be assigned in a 1:1 randomization to either the `5-AZA+ATRA' group or the `no therapy' group. Patients in the `5-AZA + ATRA' group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles. Patients will initially be observed for 3 cycles under either no therapy or combination therapy, before crossing over to receive the opposite treatment for another 3 cycles in the absence of prohibitive toxicities. After the treatment period, all patients will be followed for a total of 24 months from the start of the study or until the events leading to discontinuation are observed.

NCT ID: NCT03569241 Recruiting - Prostate Cancer Clinical Trials

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

STORM
Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined to the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment recommendations for these type of patients, different treatment approaches are currently used, mostly focusing on local ablative treatments using radiotherapy or surgery. These treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed. The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis radiotherapy (WPRT: 45 Gy in 25 fractions).

NCT ID: NCT03561220 Recruiting - Prostate Cancer Clinical Trials

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

COMPPARE
Start date: July 5, 2018
Phase: N/A
Study type: Interventional

This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.

NCT ID: NCT03536065 Recruiting - Prostate Cancer Clinical Trials

Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery

ORIOLES
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

ORIOLES is a pre-post study designed to improve quality of opioid prescribing and use after discharge for patients undergoing urologic surgery. The study will initially focus on a pre-defined cohort of patients undergoing radical prostatectomy. After the predefined study period and results are obtained, the intervention may be applied to all urologic surgeries based on the degree of improvement demonstrated by the study.

NCT ID: NCT03529643 Recruiting - Prostate Cancer Clinical Trials

Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy

Start date: May 24, 2018
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the effect of anesthetic method on the optic nerve sheath diameter in patients undergoing robot-assisted laparoscopic prostatectomy.